1. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. Issue 2 (December 2017) Authors: Weller, Michael; Butowski, Nicholas; Tran, David D; Recht, Lawrence D; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M; Wong, Mark; Hamilton, Mark G; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer;... Journal: Lancet oncology Issue: Volume 18:Issue 2(2017:Feb.) Page Start: e709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Issue 10 (October 2017) Authors: Weller, Michael; Butowski, Nicholas; Tran, David D; Recht, Lawrence D; Lim, Michael; Hirte, Hal; Ashby, Lynn; Mechtler, Laszlo; Goldlust, Samuel A; Iwamoto, Fabio; Drappatz, Jan; O'Rourke, Donald M; Wong, Mark; Hamilton, Mark G; Finocchiaro, Gaetano; Perry, James; Wick, Wolfgang; Green, Jennifer;... Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Significant Neutralizing Antibody and Cytolytic T Cell Responses to GEN-003, a Herpes Simplex Virus Immunotherapy, in a Phase 2b Study. (4th October 2017) Authors: McNeil, Lisa K; Baccari, Amy; Clemens, Veronica; Dominguez, David; Fenske, Tyler; Oliphant, Thomas; Perry, James; Siddall, Nicolle; Yuan, Jin; Heineman, Thomas; Hetherington, Seth; Flechtner, Jessica B Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗